Sunshine Biopharma (SBFM) Cash from Investing Activities (2015 - 2026)
Sunshine Biopharma (SBFM) posted Cash from Investing Activities of -$104518.0 for Q1 2026, down 108.17% on a QoQ basis from -$50209.0 in Q4 2025, and up 50.7% year-over-year from -$69353.6 in Q1 2025.
Sunshine Biopharma (SBFM) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Sunshine Biopharma's Cash from Investing Activities history runs 11 years deep, the most recent figure standing at -$104518.0 for Q1 2026.
- Quarterly Cash from Investing Activities rose 50.7% year-over-year to -$104518.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$728807.0 (up 52.13% YoY) and the FY2025 annual result came in at -$836306.0, up 57.75% from the prior year.
- Cash from Investing Activities was -$104518.0 for Q1 2026 at Sunshine Biopharma, down from -$50209.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $18859.0 in Q3 2023 and bottomed at -$14.6 million in Q4 2022.
- A 5-year average of -$1.3 million and a median of -$235746.5 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 98.16% — and 2024, when it sank 3655.86%.
- Sunshine Biopharma's Cash from Investing Activities stood at -$14.6 million in 2022, then soared by 98.16% to -$269230.0 in 2023, then soared by 63.69% to -$97770.0 in 2024, then jumped by 48.65% to -$50209.0 in 2025, then plunged by 108.17% to -$104518.0 in 2026.
- Business Quant data shows SBFM's Cash from Investing Activities at -$104518.0 in Q1 2026, -$50209.0 in Q4 2025, and -$118295.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | -104,518.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -104,518.00 |
| Mar 31, 2026 | -104,518.00 |
| Dec 31, 2025 | -50,209.00 |
| Dec 31, 2025 | -50,209.00 |
| Sep 30, 2025 | -118,295.00 |
| Sep 30, 2025 | -118,295.00 |
| Jun 30, 2025 | -455,785.00 |
| Jun 30, 2025 | -455,785.00 |
| Mar 31, 2025 | -212,017.00 |
| Mar 31, 2025 | -212,017.00 |
| Dec 31, 2024 | -97,770.00 |
| Dec 31, 2024 | -97,770.00 |
| Sep 30, 2024 | -670,599.00 |
| Sep 30, 2024 | -670,599.00 |
| Jun 30, 2024 | -542,208.00 |
| Jun 30, 2024 | -542,208.00 |
| Mar 31, 2024 | -668,736.00 |
| Mar 31, 2024 | -668,736.00 |
| Dec 31, 2023 | -269,230.00 |
| Dec 31, 2023 | -269,230.00 |